Niagen Bioscience, Inc. (NAGE) – What Are Researchers Thinking About This Stock?

Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) have earned a consensus rating of “Buy” from the five brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $10.33.

NAGE has been the topic of several research reports. HC Wainwright restated a “buy” rating on shares of Niagen Bioscience in a research note on Wednesday, July 1st. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a research note on Thursday, October 15th. Freedom Capital raised Niagen Bioscience to a “strong-buy” rating in a report on Monday, July 6th. Finally, Roth Capital reissued a “buy” rating on shares of Niagen Bioscience in a report on Wednesday, August 5th.

Niagen Bioscience Price Performance

NASDAQ NAGE opened at $2.43 on Monday. The stock has a market capitalization of $193.53 million, a price-to-earnings ratio of 13.50 and a beta of 2.02. Niagen Bioscience has a one year low of $2.42 and a one year high of $7.95. The business’s fifty day moving average is $2.92 and its 200-day moving average is $3.46.

Niagen Bioscience (NASDAQ:NAGE) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.01 earnings per share for the quarter, meeting the consensus estimate of $0.01. The company had revenue of $29.78 million during the quarter, compared to analyst estimates of $29.95 million. Niagen Bioscience had a net margin of 12.39% and a return on equity of 17.95%. Research analysts expect that Niagen Bioscience will post 0.10 EPS for the current fiscal year.

Institutional Investors Weigh In On Niagen Bioscience

Several institutional investors have recently made changes to their positions in NAGE. Stoneridge Investment Partners LLC purchased a new position in Niagen Bioscience in the 2nd quarter worth approximately $49,000. Teton Advisors LLC raised its holdings in Niagen Bioscience by 20.0% in the 1st quarter. Teton Advisors LLC now owns 30,000 shares of the company’s stock worth $132,000 after purchasing an additional 5,000 shares in the last quarter. Abel Hall LLC bought a new stake in shares of Niagen Bioscience during the third quarter valued at approximately $99,000. Chicago Partners Investment Group LLC bought a new position in Niagen Bioscience during the 1st quarter valued at approximately $214,000. Finally, Quantinno Capital Management LP grew its holdings in shares of Niagen Bioscience by 90.0% during the first quarter. Quantinno Capital Management LP now owns 50,946 shares of the company’s stock valued at $225,000 after buying an additional 24,135 shares during the last quarter. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.